Exploiting Circulating Tumour DNA to Intensify the Postoperative Treatment Resected Colon Cancer Patients

NCT05062889 · clinicaltrials.gov ↗

PHASE2

Phase

SUSPENDED

Status

477

Enrollment

OTHER

Sponsor class

Stopped due to earlier termination of the agreement between the Sponsor and Central Laboratory for screening test. Enrollment will reopen as soon as a new laboratory is identified.

Conditions

Stage II Colon Cancer
Stage III Colon Cancer
HER2-positive Colon Cancer
RAS Wild-type Colon Cancer

Interventions

DRUG: 5-Fluorouracil continuous infusion FOLFOXIRI schedule
DRUG: 5-Fluorouracil bolus FOLFOX schedule
DRUG: 5-Fluorouracil continuous infusion FOLFOX schedule
DRUG: Oxaliplatin FOLFOX and FOLFOXIRI schedule
DRUG: Oxaliplatin CAPOX schedule
DRUG: L-Leucovorin
DRUG: Capecitabine
DRUG: Irinotecan
DRUG: Trifluridine/Tipiracil
DRUG: Trastuzumab
DRUG: Tucatinib

Sponsor

Gruppo Oncologico del Nord-Ovest

Collaborators

[object Object]
[object Object]
[object Object]